Last reviewed · How we verify
NCT04467489
Biomarkers of CASH
trial testing observational in Cerebral Cavernous Malformation in 1,040 participants. Participants enrolled and being followed up; not accepting new ones.
30 April 2025
Quick facts
| Lead sponsor | University of Chicago |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 1,040 |
| Start date | 22 May 2020 |
| Primary completion | 30 April 2025 |
| Estimated completion | 30 June 2026 |
| Sites | 4 locations across United States |
Drugs / interventions tested
- observational — full drug profile →
Conditions studied
- Cerebral Cavernous Malformation — all drugs for Cerebral Cavernous Malformation →
- Cavernous Angioma — all drugs for Cavernous Angioma →
- Hemorrhagic Microangiopathy — all drugs for Hemorrhagic Microangiopathy →
Sponsor
University of Chicago
Who can join
18 and older, any sex, with Cerebral Cavernous Malformation or Cavernous Angioma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The project aims to develop prognostic and diagnostic blood tests for symptomatic brain hemorrhage in patients diagnosed with cavernous angiomas, a critical clinical challenge in a disease affecting more than a million Americans. We further examine whether blood biomarkers can replace or enhance the accuracy of advanced imaging in association with lesional bleeding. The project tests a novel integrational approach of biomarker development in a mechanistically defined cerebrovascular disease, with a clinically relevant context of use.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Artificial Intelligence in Neurosurgery: A State-of-the-Art Review from Past to Future.
Tangsrivimol JA, Schonfeld E, Zhang M, Veeravagu A, et al · · 2023 · cited 43× · PMID 37510174 · DOI 10.3390/diagnostics13142429 -
A Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH).
Girard R, Li Y, Stadnik A, Shenkar R, et al · · 2021 · cited 24× · PMID 33469662 · DOI 10.1093/neuros/nyaa478
Verify or expand the search:
- PubMed search for NCT04467489
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of observational
Trials testing the same drug.
- NCT06822764 — Mental Processes for Rating Pain Intensity · enrolling by invitation
- NCT06162234 — Wuhan High Myopia Study · recruiting
- NCT06066736 — Risks Factors and Outcome of Recurrences in Patients With Ventilator-Associated Pneumonias (REVAP) · completed
- NCT06403631 — Supporting Mental Health in Daily Life After the Diagnosis of Multiple Sclerosis · recruiting
- NCT05768906 — (DIS)AGreement of Relatives Regarding Ethical End-of-life Decisions in ICU. · completed
Other University of Chicago trials
Trials by the same sponsor.
- NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
- NCT07354100 — Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy · Phase 1, PHASE2 · not yet recruiting
- NCT06446661 — Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia · NA · not yet recruiting
- NCT07179315 — A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Tr · Phase 2 · not yet recruiting
- NCT07126561 — Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04467489 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Chicago
- Last refreshed: 11 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04467489.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing